A detailed history of Northern Trust Corp transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 78,975 shares of RLMD stock, worth $266,145. This represents 0.0% of its overall portfolio holdings.

Number of Shares
78,975
Previous 81,049 2.56%
Holding current value
$266,145
Previous $376,000 37.23%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.93 - $4.94 $6,076 - $10,245
-2,074 Reduced 2.56%
78,975 $236,000
Q1 2024

May 14, 2024

SELL
$3.1 - $6.8 $47,175 - $103,482
-15,218 Reduced 15.81%
81,049 $376,000
Q4 2023

Feb 13, 2024

BUY
$2.45 - $4.22 $120,454 - $207,476
49,165 Added 104.38%
96,267 $398,000
Q3 2023

Nov 13, 2023

SELL
$2.48 - $3.79 $863 - $1,318
-348 Reduced 0.73%
47,102 $141,000
Q2 2023

Aug 11, 2023

SELL
$2.22 - $3.54 $360,841 - $575,395
-162,541 Reduced 77.4%
47,450 $116,000
Q1 2023

May 15, 2023

SELL
$2.24 - $4.76 $41,121 - $87,384
-18,358 Reduced 8.04%
209,991 $474,000
Q4 2022

Feb 13, 2023

SELL
$2.17 - $35.84 $50,187 - $828,907
-23,128 Reduced 9.2%
228,349 $796,000
Q3 2022

Nov 14, 2022

BUY
$18.3 - $37.02 $25,729 - $52,050
1,406 Added 0.56%
251,477 $9.31 Million
Q2 2022

Aug 12, 2022

BUY
$16.5 - $30.34 $73,177 - $134,557
4,435 Added 1.81%
250,071 $4.75 Million
Q1 2022

May 13, 2022

BUY
$16.72 - $26.99 $1.2 Million - $1.94 Million
71,704 Added 41.23%
245,636 $6.63 Million
Q4 2021

Feb 08, 2022

BUY
$16.93 - $26.82 $181,608 - $287,698
10,727 Added 6.57%
173,932 $3.92 Million
Q3 2021

Nov 15, 2021

BUY
$21.86 - $34.77 $148,801 - $236,679
6,807 Added 4.35%
163,205 $4.28 Million
Q2 2021

Aug 13, 2021

SELL
$29.55 - $39.15 $186,046 - $246,488
-6,296 Reduced 3.87%
156,398 $5.01 Million
Q1 2021

May 12, 2021

SELL
$31.52 - $39.28 $323,836 - $403,562
-10,274 Reduced 5.94%
162,694 $5.73 Million
Q4 2020

Feb 11, 2021

SELL
$29.88 - $39.8 $121,014 - $161,190
-4,050 Reduced 2.29%
172,968 $5.55 Million
Q3 2020

Nov 16, 2020

SELL
$34.42 - $43.78 $182,598 - $232,252
-5,305 Reduced 2.91%
177,018 $6.66 Million
Q2 2020

Aug 14, 2020

BUY
$31.59 - $49.98 $4.92 Million - $7.78 Million
155,710 Added 585.09%
182,323 $8.16 Million
Q1 2020

May 14, 2020

BUY
$23.78 - $50.12 $55,454 - $116,879
2,332 Added 9.6%
26,613 $908,000
Q4 2019

Feb 14, 2020

BUY
$10.1 - $47.18 $245,238 - $1.15 Million
24,281 New
24,281 $947,000

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $96.4M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.